{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T04:02:05Z","timestamp":1770523325209,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00259-024-07042-9","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T02:43:55Z","timestamp":1734749035000},"page":"801-805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Editorial Commentary: Should \u201cheterogeneous response\u201d be considered as new category for assessing treatment response in patients with breast cancer?"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-9349","authenticated-orcid":false,"given":"Sofia C.","family":"Vaz","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-9175","authenticated-orcid":false,"given":"David","family":"Groheux","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-3538","authenticated-orcid":false,"given":"Thiemo","family":"van Nijnatten","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1832-1083","authenticated-orcid":false,"given":"Lidija","family":"Antunovic","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6692-2249","authenticated-orcid":false,"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7212-6521","authenticated-orcid":false,"given":"Felix","family":"Mottaghy","sequence":"additional","affiliation":[]},{"given":"Maria Joao","family":"Cardoso","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7913-8827","authenticated-orcid":false,"given":"Christopher","family":"Riedl","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1817-2743","authenticated-orcid":false,"given":"Lioe-Fee","family":"de Geus-Oei","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7953-0113","authenticated-orcid":false,"given":"Gary A.","family":"Ulaner","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"key":"7042_CR1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","journal-title":"J Nucl Med"},{"key":"7042_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.10.017","author":"M Tazdait","year":"2018","unstructured":"Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.017.","journal-title":"Eur J Cancer"},{"key":"7042_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04573-4","author":"O Humbert","year":"2020","unstructured":"Humbert O, Cadour N, Paquet M, Schiappa R, Poudenx M, Chardin D, et al. 18 FDG PET\/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. Eur J Nuc Med Mol Imaging. 2020. https:\/\/doi.org\/10.1007\/s00259-019-04573-4.","journal-title":"Eur J Nuc Med Mol Imaging"},{"key":"7042_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113483","author":"D Lang","year":"2020","unstructured":"Lang D, Wahl G, Poier N, Graf S, Kiesl D, Lamprecht B, et al. Impact of PET\/CT for Assessing Response to Immunotherapy\u2014A Clinical Perspective. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9113483.","journal-title":"J Clin Med"},{"key":"7042_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05780-2","author":"E Lopci","year":"2022","unstructured":"Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, et al. Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [(18)F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging. 2022. https:\/\/doi.org\/10.1007\/s00259-022-05780-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7042_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2010.05.021","author":"V Huyge","year":"2010","unstructured":"Huyge V, Garcia C, Alexiou J, Ameye L, Vanderlinden B, Lemort M, et al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Oncol (R Coll Radiol). 2010. https:\/\/doi.org\/10.1016\/j.clon.2010.05.021.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"7042_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.566297","author":"O Humbert","year":"2020","unstructured":"Humbert O, Chardin D. Dissociated Response in Metastatic Cancer: An Atypical Pattern Brought Into the Spotlight With Immunotherapy. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.566297.","journal-title":"Front Oncol"},{"key":"7042_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000. https:\/\/doi.org\/10.1038\/35021093.","journal-title":"Nature"},{"key":"7042_CR9","doi-asserted-by":"publisher","DOI":"10.1148\/rg.220122","author":"AS Parihar","year":"2023","unstructured":"Parihar AS, Dehdashti F, Wahl RL. FDG PET\/CT\u2013based Response Assessment in Malignancies. Radiographics. 2023. https:\/\/doi.org\/10.1148\/rg.220122.","journal-title":"Radiographics"},{"key":"7042_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0672-3","author":"ND Klemen","year":"2019","unstructured":"Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, et al. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. J Immunother Cancer. 2019. https:\/\/doi.org\/10.1186\/s40425-019-0672-3.","journal-title":"J Immunother Cancer"},{"key":"7042_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00363-1","author":"L Guo","year":"2023","unstructured":"Guo L, Kong D, Liu J, Zhan L, Luo L, Zheng W, et al. Breast cancer heterogeneity and its implication in personalized precision therapy. Exp Hematol Oncol. 2023. https:\/\/doi.org\/10.1186\/s40164-022-00363-1.","journal-title":"Exp Hematol Oncol"},{"key":"7042_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00165-4","author":"A Li","year":"2021","unstructured":"Li A, Keck JM, Parmar S, Patterson J, Labrie M, Creason AL, et al. Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. npj Precis Oncol. 2021. https:\/\/doi.org\/10.1038\/s41698-021-00165-4.","journal-title":"npj Precis Oncol"},{"key":"7042_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06696-9","author":"SC Vaz","year":"2024","unstructured":"Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, et al. Joint EANM-SNMMI guideline on the role of 2-[(18)F]FDG PET\/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI\/ESR, and EUSOMA). Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06696-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7042_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics9030106","author":"F Helland","year":"2019","unstructured":"Helland F, Hallin Henriksen M, Gerke O, Vogsen M, H\u00f8ilund-Carlsen PF, Hildebrandt MG. FDG-PET\/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review. Diagnostics (Basel). 2019. https:\/\/doi.org\/10.3390\/diagnostics9030106.","journal-title":"Diagnostics (Basel)"},{"key":"7042_CR15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263358","author":"M Vogsen","year":"2023","unstructured":"Vogsen M, Harbo F, Jakobsen NM, Nissen HJ, Dahlsgaard-Wallenius SE, Gerke O, et al. Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing (18)F-FDG PET\/CT with Conventional CT. J Nucl Med. 2023. https:\/\/doi.org\/10.2967\/jnumed.121.263358.","journal-title":"J Nucl Med"},{"key":"7042_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103806","author":"D Groheux","year":"2024","unstructured":"Groheux D, Vaz SC, Poortmans P, Mann RM, Ulaner GA, Cook GJR, et al. Role of [18F]FDG PET\/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines. Breast. 2024. https:\/\/doi.org\/10.1016\/j.breast.2024.103806.","journal-title":"Breast"},{"key":"7042_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32727-w","author":"M Vogsen","year":"2023","unstructured":"Vogsen M, Naghavi-Behzad M, Harbo FG, Jakobsen NM, Gerke O, Asmussen JT, et al. 2-[(18)F]FDG-PET\/CT is a better predictor of survival than conventional CT: a prospective study of response monitoring in metastatic breast cancer. Sci Rep. 2023. https:\/\/doi.org\/10.1038\/s41598-023-32727-w.","journal-title":"Sci Rep"},{"key":"7042_CR18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.157909","author":"GA Ulaner","year":"2016","unstructured":"Ulaner GA, Riedl CC, Dickler MN, Jhaveri K, Pandit-Taskar N, Weber W. Molecular Imaging of Biomarkers in Breast Cancer. J Nucl Med. 2016. https:\/\/doi.org\/10.2967\/jnumed.115.157909.","journal-title":"J Nucl Med"},{"key":"7042_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081.","journal-title":"Eur J Cancer"},{"key":"7042_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00508-3","author":"V Debien","year":"2023","unstructured":"Debien V, De Caluw\u00e9 A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. npj Breast Cancer. 2023. https:\/\/doi.org\/10.1038\/s41523-023-00508-3.","journal-title":"npj Breast Cancer"},{"key":"7042_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/op.22.00483","author":"SL Jacob","year":"2023","unstructured":"Jacob SL, Huppert LA, Rugo HS. Role of Immunotherapy in Breast Cancer. JCO Oncol Prac. 2023. https:\/\/doi.org\/10.1200\/op.22.00483.","journal-title":"JCO Oncol Prac"},{"key":"7042_CR22","doi-asserted-by":"crossref","unstructured":"Vaz SC, Graff SL, Ferreira AR, Debiasi M, de Geus-Oei. L-F. PET\/CT in Patients with Breast Cancer Treated with Immunotherapy. Cancers; 2023.","DOI":"10.3390\/cancers15092620"},{"key":"7042_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00412-0","author":"X Zheng","year":"2022","unstructured":"Zheng X, Lu T, Wu S, Peng W, Miao Q, Jiang K, et al. Tumour response heterogeneity as a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma: a retrospective analysis. Lancet Oncol. 2022. https:\/\/doi.org\/10.1016\/S1470-2045(22)00412-0.","journal-title":"Lancet Oncol"},{"key":"7042_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06764-0","author":"O Lokre","year":"2024","unstructured":"Lokre O, Perk TG, Weisman AJ, Govindan RM, Chen S, Chen M, et al. Quantitative evaluation of lesion response heterogeneity for superior prognostication of clinical outcome. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06764-0.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-07042-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-07042-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-07042-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T04:27:34Z","timestamp":1737520054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-07042-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["7042"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-07042-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"21 December 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}